WHO model list of essential in vitro diagnostics
The WHO model list of essential in vitro diagnostics, or WHO list of essential diagnostic tests (EDL) is a World Health Organization (WHO) priority list of medical tests that provides guidance for individual countries on which tests to use and which not to.[1][2] It was first published in 2018,[1][3] then revised in 2019,[1][3] and a third edition was published in 2020.[1][4]
Tests in community settings where there is no laboratory, are divided into general tests and tests that are disease-specific.[5] Diseases that can be tested for in the community without laboratory facilities include: Chagas disease, cholera, COVID-19, diabetes mellitus, hepatitis B and C, HIV, influenza, malaria, Streptococcal pharyngitis, sickling disorders, syphilis, tuberculosis and visceral leishmaniasis.[5] Where there is a health care facility with laboratories, tests are divided into either general tests or disease-specific tests for clinical laboratories, and disease-specific tests for blood screening laboratories.[5] For each group of tests, the EDL specifies the test's name, purpose, assay format and type of specimen.[6]
Background
editWithout reliable tests, health care providers rely mainly on empirical treatments, which result in higher antibiotic use, use of multiple other medicines and underdiagnosis.[7] The tests in the EDL are assessed using the REASSURED criteria; real time connectivity, ease of specimen collection, affordable, sensitive, specific, user-friendly, rapid and robust, results availability, equipment, and delivery.[1] It allows treatments to be more precise.[7]
The EDL is a priority list of medical tests, which the WHO defines as "one of the six building blocks of a health system".[1] The EDL provides guidance for individual countries, on which medical tests to use and which not to.[1] A Strategic Group of Experts on In Vitro Diagnostics (SAGE IVD) is appointed by the WHO to advise on its development as it is regularly reviewed and expanded.[8] Different countries can adapt it; the Indian Council of Medical Research produced its own version of the EDL in 2019, a year after the first edition.[9]
Publications
editThe first edition was published by the WHO on 15 May 2018, and complements the WHO Model List of Essential Medicines (EML), which was published more than 40 years earlier.[1][8] More than 150 countries have adapted the WHO Model List of Essential Medicines.[7] A second edition was published in July 2019,[3] and a third in 2020.[4]
Content
editIn the EDL, essential diagnostic tests are defined as those "that satisfy the priority health care needs of the population and are selected with due regard to disease prevalence and public health relevance, evidence of efficacy and accuracy, and comparative cost-effectiveness."[8]
The first edition contained 62 test categories and the second was updated to include 122 test categories.[2] The categories of tests include: general laboratory tests and disease-specific tests such as for hepatitis B and C, HIV, HPV, malaria, syphilis and tuberculosis.[1][8] The third edition added a "Do Not Do" recommendation, for tests deemed no longer useful.[2] Some tests such as a quick test for malaria, do not require a laboratory, a health care setting or professional, or electricity.[10]
For each group of tests, the EDL specifies the test's name, purpose, assay format and type of specimen.[6] Supporting WHO Guidelines or publications are linked and brands are not referenced.[6] The EDL includes recommendations of types of tests that should be available in community settings where there are no laboratories, such as for anaemia, malaria or pregnancy.[6] Laboratory tests such as those for testing for cancers are recommended for hospitals and laboratories.[6]
Healthcare settings without laboratories
editTests in community settings without laboratories are divided into general tests and tests that are disease-specific.[5] These include tests that are recommended for use in primary care units, doctors' offices, community clinics, ambulatory care and at home such as for self-testing.[5]
| Specialty | Test | Test purpose | Assay | Specimen type |
|---|---|---|---|---|
| Blood typing | ABO blood groups and Rhesus (Rh) factor | Blood group | Slide agglutination test | Blood from capillary or vein |
| Clinical chemistry | Albumin | Detect/monitor kidney disease | Urine test strip | Urine |
| Bilirubin | Detect/monitor liver disease and bile duct disorders | Urine test strip | Urine | |
| Glucose | Detect low glucose | Glucose meter | Urine | |
| Ketones | Detect/monitor ketosis (diabetes, starvation, pregnancy, diabetic ketoacidosis) | Dipstick | Urine | |
| Urinalysis test strips | Detect leukocytes or nitrites to help diagnose urinary tract infections | Dipstick | Urine | |
| Haematology | Erythrocyte sedimentation rate (ESR) | To detect inflammation when C-reactive protein (CRP) unavailable | Westergren | Blood from vein |
| Hemoglobin (Hb) | Diagnose/monitor anaemia and certain drugs (e.g. zidovudine), and to screen potential blood donors | Haemoglobinometer | Blood from capillary or vein | |
| Marker for severe infections (e.g. malaria), Help diagnose intravascular haemolysis, kidney conditions, rhabdomyolysis (myoglobinuria) | Dipstick | Urine | ||
| Pregnancy testing | Human chorionic gonadotrophin (hCG) | Detect early pregnancy | Rapid diagnostic test (RDT) (dipstick and cassette), latex agglutination | Early morning urine |
Tests in community settings without laboratories, which are disease-specific include tests for Chagas disease, cholera, COVID-19, diabetes mellitus, hepatitis B and C, HIV, influenza, malaria, Streptococcal pharyngitis, sickling disorders, syphilis, tuberculosis, visceral leishmaniasis.[5]
Healthcare settings with laboratories
editWhere there is a health care facility with laboratories, tests are divided into either general tests or disease-specific tests for clinical laboratories, and disease-specific tests for blood screening laboratories.[5]
Discontinued tests
editThe HIV western blot test and the Mycobacterium tuberculosis serology test are not recommended.[5]
References
edit- ^ a b c d e f g h i Bernabé-Ortiz, Antonio; Zafra-Tanaka, Jessica H.; Moscoso-Porras, Miguel; Sampath, Rangarajan; Vetter, Beatrice; Miranda, J. Jaime; Beran, David (9 March 2021). "Diagnostics and monitoring tools for noncommunicable diseases: a missing component in the global response". Globalization and Health. 17 (1): 26. doi:10.1186/s12992-021-00676-6. ISSN 1744-8603. PMC 7941936. PMID 33750391.
- ^ a b c "The selection and use of essential in vitro diagnostics-2020". www.who.int. World Health Organization. p. 2. Retrieved 20 August 2021.
- ^ a b c Cam, Yann Le. "WHO Essential Medicines and in Vitro Diagnostics Lists: Why, What & How" (PDF). Rarediseasesinternational.org. Rare Diseases International.
- ^ a b The selection and use of essential in vitro diagnostics: report of the third meeting of the WHO Strategic Advisory Group of Experts on In Vitro Diagnostics, 2020 (including the third WHO model list of essential in vitro diagnostics). Geneva: World Health Organization; 2021 (WHO Technical Report Series, No. 1031). Licence: CC BY-NC-SA 3.0 IGO.
- ^ a b c d e f g h i "The selection and use of essential in vitro diagnostics - 2020". www.who.int. World Health Organization. pp. 272–352. Retrieved 20 August 2021.
- ^ a b c d e "Brochure: The WHO model list of essential in vitro diagnostics (EDL)". www.who.int. 27 January 2021. Retrieved 27 August 2021.
- ^ a b c Pai, Madhukar; Walia, Kamini; Boehme, Catharina C. (1 October 2019). "Essential medicines and essential diagnostics: a package deal". The Lancet Public Health. 4 (10): e492. doi:10.1016/S2468-2667(19)30165-3. ISSN 2468-2667. PMID 31451443. S2CID 201757992.
- ^ a b c d Moussy, Francis Gabriel; Berumen, Adriana Velazquez; Pai, Madhukar (November 2018). "The WHO list of essential in vitro diagnostics: Development and next steps". eBioMedicine. 37: 1–2. doi:10.1016/j.ebiom.2018.10.070. ISSN 2352-3964. PMC 6286302. PMID 30389503.
- ^ Vijay, Sonam; Gangakhedkar, Raman R; Shekhar, Chander; Walia, Kamini (1 March 2021). "Introducing a national essential diagnostics list in India". Bulletin of the World Health Organization. 99 (3): 236–238. doi:10.2471/BLT.20.268037 (inactive 5 December 2024). ISSN 0042-9686. PMC 7941112. PMID 33716346.
{{cite journal}}: CS1 maint: DOI inactive as of December 2024 (link) - ^ "First Essential Diagnostics List". AEFJN. 1 June 2018. Retrieved 28 August 2021.
Further reading
edit- Technical specifications for selection of essential in vitro diagnostics for SARS-COV-2 (PDF). World Health Organization. 14 June 2021.
- "Global Action Plan for the Prevention and Control of NCDs 2013-2020". www.who.int.